Acurx Pharmaceuticals, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $6.6M
- Price
- $1.25
- % Change (Daily % change from the live per-ticker quote feed.)
- -3.85%
- Volume
- 74.1K
About
Acurx Pharmaceuticals, Inc. functions as a clinical-stage biopharmaceutical firm focused on developing innovative antibiotic treatments for bacterial infections. The company's primary drug candidate is ibezapolstat, an antibiotic that utilizes a novel mechanism of action by targeting the polymerase IIIC enzyme. Ibezapolstat has successfully completed Phase II clinical trials for addressing Clostridium difficile infections. Additionally, Acurx is progressing with ACX-375C, an investigational therapeutic suitable for both oral and injectable administration. This compound is being developed to combat various gram-positive bacteria, including resistant strains such as methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus, and penicillin-resistant Streptococcus pneumoniae. Acurx Pharmaceuticals, Inc. was established in 2017 and is headquartered in Staten Island, New York.
Quick stats
Shares outstanding5.3M
Computed float3.8M
Float / shares72.1%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001736243
Websitehttps://www.acurxpharma.com
AI Summary
AI-generated1/26
minorneutraloperations update
Acurx Pharmaceuticals Takes Its Antibiotics Story Global Through a 12-Month Series with New to The Street
Acurx Pharmaceuticals signed a 12-month media series with New to The Street, bringing monthly long-form executive interviews to investors via Bloomberg Television sponsored programming in the U.S., Latin America, MENA and Southeast Asia.
The program includes distribution on New to The Street TV, TV commercials and accredited investor events; the content is explicitly paid sponsored promotion.
The series coincides with clinical momentum: first patient enrolled in the IBZ-PATHFINDER Phase 2 trial in multiply-recurrent CDI and FDA guidance that a single Phase 3 trial could support an NDA for ibezapolstat.
This is investor-marketing, not a fundamental disclosure; the clinical updates are recaps of previously reported progress.
Red flags
- Paid sponsored content / promotional media arrangement rather than issuer business disclosure